Major Shareholder Exits Ventyx Biosciences Following Eli Lilly Merger Completion

summarizeSummary

A significant beneficial owner, Somasundaram Subramaniam and affiliated entities, has fully exited their position in Ventyx Biosciences, Inc. following the company's merger with Eli Lilly and Company.

check_boxKey Events

• Major Shareholder Exit

  Somasundaram Subramaniam and affiliated entities, previously a beneficial owner of more than five percent, have ceased to own any securities of Ventyx Biosciences, Inc.

• Merger-Driven Disposition

  The disposition of shares occurred on March 4, 2026, as a direct consequence of the completed merger between Ventyx Biosciences, Inc. and Eli Lilly and Company.

• Cash Conversion

  All beneficially owned shares were converted into the right to receive $14.00 per share in cash, less any applicable tax withholding, at the effective time of the merger.

• Prior Share Distribution

  Prior to the merger, on February 27, 2026, 474,632 shares held by NSV Partners III, L.P. and 220,086 shares held by New Science Ventures, LLC were distributed pro rata for no consideration.

auto_awesomeAnalysis

This Schedule 13D/A filing confirms that Somasundaram Subramaniam and associated entities, previously a significant beneficial owner, no longer hold any securities in Ventyx Biosciences, Inc. This exit is a direct result of the company's merger with Eli Lilly and Company, which was completed on March 4, 2026. All beneficially owned shares were converted into cash at $14.00 per share. While the merger itself was the primary market-moving event, this filing provides a formal update on the final disposition of shares by a major investor group.